Intra-Cellular Therapies, Inc. (ITCI)
| Previous Close | 76.91 |
| Open | 76.52 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 76.17 - 78.02 |
| 52 Week Range | 45.50 - 84.89 |
| Volume | |
| Avg. Volume | 557,121 |
| Market Cap | 8.223B |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings Date | Oct 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 96.17 |
GlobeNewswireIntra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, October 30, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2024. To attend th
Insider MonkeyIntra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds
We recently compiled a list of the 10 Most Promising Mid-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the other promising mid-cap stocks. The S&P 500 May Hit 6,000 in 2024 September closed on a high note, opening a wealth […]
